Samik Pharm Co (014950.KQ) Stock Price

Samik Pharm Co Price

CLOSED
7,750.00
​
Market closed

For Samik Pharm Co, the net margin of -1.3% is down versus 5.8% a few years ago.

Samik Pharm Co stock price

Access this data via the Eulerpool API

Samik Pharm Co business model & stock analysis

Samik Pharm Co Ltd is a KR-based company operating in industry. The company is headquartered in Incheon, Incheon. The company went IPO on 2025-10-27. Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The firm is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The firm sells its products in domestic and overseas markets.

Frequently asked questions about Samik Pharm Co

Converted at the current exchange rate, the Samik Pharm Co share trades at 5.15 EUR (7,750.00 KRW).

The revenue cannot currently be calculated for Samik Pharm Co.

The profit cannot currently be calculated for Samik Pharm Co.

The P/E ratio cannot be calculated for Samik Pharm Co at the moment.

The P/S cannot be calculated for Samik Pharm Co currently.

The Eulerpool Quality Score for Samik Pharm Co is 2/10.

The ISIN of Samik Pharm Co is KR7014950000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Samik Pharm Co is 014950.KQ. The ticker symbol is used to trade Samik Pharm Co shares on the stock exchange.

Fair ValueTerminal
6,355.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website samik.co.kr
Country
South Korea
Currency
KRW
Initial public offering
Oct 27, 2025
ISIN
KR7014950000
Cusip
Y7T68J104
Market capitalization
71.08 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
20.94
P/B Ratio
1.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.05 %
Last updated Oct 10, 2026, 3:47 PM

Samik Pharm Co Peer Group